Welcome to Pangaea insights
Our collective intelligence provides an unrivalled breadth and depth of knowledge.
Pangaea’s ongoing relationships with key industry stakeholders facilitate continuous updates and dissemination of relevant market intelligence. Check back often for new posts!
Pangaea Express: One Step Closer to Drug Importation
December 24, 2019
So where are we regarding timing before the flood gates open?
Pangaea Express: Final Amendments for ODB Act and DIDFA
December 17, 2019
It has taken significant time to mend the relationship between pharmacy and the Ontario government since the 2010 pharmacy rallies at Queen’s Park in response to the elimination of professional allowances.
Pangaea Express: Alberta Next Up with a Biosimilars Initiative
December 13, 2019
This was not a surprise as rumblings about Alberta taking the biosimilars plunge had been circulating for a few months.
Pangaea Express: PSPs Regulations in the updated IMC Code
December 12, 2019
While the changes to the PSP funding may not be a surprise to some given the growing lens of transparency within the industry, this revision could have significant implications.
Sunsetting the brand: Is this the best strategy when a product will lose exclusivity?
November 28, 2019
Loss of exclusivity requires alot of effort with minimal financial reward for maintaining the life of a brand.
Pangaea Express: PMPRB Guidelines
November 22, 2019
The Draft PMPRB Guidelines were released yesterday to explain how the amended Patented Medicines Regulations, that go into effect July 1, 2020 will be implemented.
A generic biologic in Canada?
November 12, 2019
Forteo (teriparatide, Lilly) is a biologic manufactured using recombinant DNA technology.
Pangaea Express: Mandatory Reporting by Hospitals of Serious ADRs and MDIs
July 9, 2019
The Regulations regarding mandatory reporting of serious adverse drug reactions (ADRs) and medical device incidents (MDIs) by hospitals, proposed last summer, have now been adopted and will come into effect by December 16, 2019.
Pangaea Express: Advisory Council of National Pharmacare Final Recommendations
June 13, 2019
Universal, single-payer, public pharmacare in Canada.
Pangaea Express: BC Bold on Biosimilars
May 28, 2019
It has been some time coming but the speculation is over now. BC is the first province to switch patients from certain innovator biologics to their biosimilars.